Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
09 janv. 2023 07h00 HE
|
Kronos Bio, Inc.
Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage Kronos Bio’s expertise in transcriptional...
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
11 déc. 2022 10h00 HE
|
Kronos Bio, Inc.
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio’s...
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
07 déc. 2022 16h05 HE
|
Kronos Bio, Inc.
Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other transcriptionally addicted tumors Data demonstrate achievement of target engagement goal,...
Kronos Bio Announces Participation in Upcoming Investor Conferences
22 nov. 2022 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
08 nov. 2022 16h10 HE
|
Kronos Bio, Inc.
Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270.3 million in cash, cash equivalents...
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
08 nov. 2022 16h05 HE
|
Kronos Bio, Inc.
Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio’s next generation SYK inhibitor,...
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
12 oct. 2022 04h04 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other...
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
22 août 2022 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first...
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
16 août 2022 16h05 HE
|
Kronos Bio, Inc.
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is...